[go: up one dir, main page]

ES2140078T3 - Citostaticos modificados con hidratos de carbono. - Google Patents

Citostaticos modificados con hidratos de carbono.

Info

Publication number
ES2140078T3
ES2140078T3 ES96910926T ES96910926T ES2140078T3 ES 2140078 T3 ES2140078 T3 ES 2140078T3 ES 96910926 T ES96910926 T ES 96910926T ES 96910926 T ES96910926 T ES 96910926T ES 2140078 T3 ES2140078 T3 ES 2140078T3
Authority
ES
Spain
Prior art keywords
modified
cytostatics
carbon hydrates
hydrates
carbon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96910926T
Other languages
English (en)
Inventor
Hans-Georg Lerchen
Dem Bruch Karsten Von
Uwe Petersen
Jorg Baumgarten
Norbert Piel
Horst-Peter Antonicek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of ES2140078T3 publication Critical patent/ES2140078T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

LA INVENCION TRATA DE CITOESTATICOS ESPECIFICOS PARA TUMORES AL HABER SIDO MODIFICADOS CON AZUCAR. UNOS SPACERS APROPIADOS GARANTIZAN LA ESTABILIDAD SEROLOGICA ADEMAS DE UN EFECTO INTRACELULAR.
ES96910926T 1995-04-04 1996-03-22 Citostaticos modificados con hidratos de carbono. Expired - Lifetime ES2140078T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19512484A DE19512484A1 (de) 1995-04-04 1995-04-04 Kohlenhydratmodifizierte Cytostatika

Publications (1)

Publication Number Publication Date
ES2140078T3 true ES2140078T3 (es) 2000-02-16

Family

ID=7758679

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96910926T Expired - Lifetime ES2140078T3 (es) 1995-04-04 1996-03-22 Citostaticos modificados con hidratos de carbono.

Country Status (27)

Country Link
US (1) US6271342B1 (es)
EP (1) EP0819135B1 (es)
JP (1) JPH11502860A (es)
KR (1) KR19980703591A (es)
CN (1) CN1185786A (es)
AT (1) ATE186738T1 (es)
AU (1) AU713466B2 (es)
BG (1) BG63048B1 (es)
BR (1) BR9604825A (es)
CA (1) CA2217164A1 (es)
CZ (1) CZ291098B6 (es)
DE (2) DE19512484A1 (es)
DK (1) DK0819135T3 (es)
EE (1) EE03619B1 (es)
ES (1) ES2140078T3 (es)
GR (1) GR3032605T3 (es)
HU (1) HUP9800513A3 (es)
IS (1) IS1822B (es)
MX (1) MX9707613A (es)
NO (1) NO974564L (es)
NZ (1) NZ305855A (es)
PL (1) PL183574B1 (es)
RU (1) RU2170234C2 (es)
SK (1) SK281785B6 (es)
TW (1) TW384290B (es)
UA (1) UA61054C2 (es)
WO (1) WO1996031532A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001504453A (ja) * 1996-09-30 2001-04-03 バイエル・アクチエンゲゼルシヤフト 改変カンプトテシン誘導体からの複合糖質（２０―ｏ―結合）
DE19640970A1 (de) * 1996-10-04 1998-04-16 Bayer Ag Modifizierte Cytostatika
JP3101710B2 (ja) 1997-02-28 2000-10-23 工業技術院長 硫酸化オリゴ糖化合物
ID23424A (id) * 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
JP4669607B2 (ja) 1997-09-15 2011-04-13 ザ プロクター アンド ギャンブル カンパニー 抗微生物キノロン類、その組成物およびその使用
US6387928B1 (en) 1997-09-15 2002-05-14 The Procter & Gamble Co. Antimicrobial quinolones, their compositions and uses
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
DE10005275A1 (de) * 2000-02-07 2001-08-09 Bayer Ag Neuartige Glycokonjugate
US7220824B1 (en) * 2000-08-28 2007-05-22 Bayer Aktiengesellschaft Integrin-mediated drug targeting
EP1219634A1 (en) * 2000-12-27 2002-07-03 Bayer Aktiengesellschaft Cytostatic-glycoconjugates having specifically cleavable peptidic linking units
EP1238678A1 (en) * 2001-03-08 2002-09-11 Bayer Aktiengesellschaft Enzyme-activated cytostatic conjugates with integrin ligands
WO2003040093A2 (de) * 2001-11-09 2003-05-15 Bayer Healthcare Ag Isotopencodierte affinitätsmarker 2
US7199149B2 (en) * 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
US20050227324A1 (en) 2003-12-19 2005-10-13 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
HRP20110558T1 (hr) 2006-03-28 2011-09-30 Warner Chilcott Company Malatne soli i polimorfi od (3s, 5s)-7-[3-amino-5-metil-piperidinil]-1-ciklopropil-1, 4-dihidro-8-metoksi-4-okso-3-kinolinkarboksilne kiseline
WO2007110836A1 (en) 2006-03-28 2007-10-04 The Procter & Gamble Company A hydride reduction process for preparing quinolone intermediates
US7456279B2 (en) 2006-03-28 2008-11-25 The Procter & Gamble Company Coupling process for preparing quinolone intermediates
JP2018509384A (ja) * 2015-01-06 2018-04-05 イミューノヴァクシーン テクノロジーズ インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リピドａ模倣体、調製方法、及びその使用
CN113599533A (zh) * 2015-11-25 2021-11-05 乐高化学生物科学股份有限公司 包含分支接头的抗体-药物缀合物及其相关方法
RS65660B1 (sr) 2015-11-25 2024-07-31 Ligachem Biosciences Inc Konјugati koji sadrže samozapaljive grupe i postupci povezani sa njima
KR101938800B1 (ko) 2017-03-29 2019-04-10 주식회사 레고켐 바이오사이언스 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
JP7459063B2 (ja) 2018-05-09 2024-04-01 レゴケム バイオサイエンシズ， インク． 抗－ｃｄ１９抗体薬物複合体に関連する組成物および方法
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
KR102865327B1 (ko) * 2021-10-06 2025-09-29 주식회사 삼양사 포화 퓨로디옥신 유도체 화합물 및 그의 이차전지용 첨가제 용도

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5977356A (ja) * 1982-06-30 1984-05-02 Fuji Photo Film Co Ltd 螢光アツセイ用多層分析要素およびそれを用いる螢光アツセイ法
DE3611194A1 (de) * 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
EP0284071B1 (en) * 1987-03-26 1994-06-08 Neorx Corporation Metal-radionuclide-labeled proteins and glycoproteins for diagnosis and therapy
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4980343A (en) * 1988-10-27 1990-12-25 Bayer Aktiengesellschaft Aminooxodihydroisoindoloquinazoline carcinostatic agents
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
CA2031803C (en) * 1989-12-13 2001-05-29 Ramakrishnan Nagarajan Improvements in or relating to glycopeptide deriveratives
US5160727A (en) * 1990-02-13 1992-11-03 Warner-Lambert Company Tumor cell sensitization method using quinazolinedione derivatives
US5965695A (en) 1990-05-15 1999-10-12 Chiron Corporation Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such
US5420297A (en) 1990-10-24 1995-05-30 Fujisawa Pharmaceutical Co., Ltd. Peptides having substance P antagonistic activity
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
DE4106101A1 (de) * 1991-02-27 1992-09-03 Bayer Ag Fucose-markierte cytostatika
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
DE4120646A1 (de) * 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
EP0545198B1 (de) 1991-11-29 1999-09-15 Hoechst Aktiengesellschaft Peptide mit insulinartiger Wirkung
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
AU662434B2 (en) 1992-08-07 1995-08-31 Sankyo Company Limited Peptides capable of inhibiting the activity of HIV protease, their preparation and their use
US5872207A (en) 1992-09-04 1999-02-16 Sanofi Pharmaceuticals, Inc. N-terminal-marked peptides immobilized on glass beads and method of preparation and method of use thereof
IL106998A0 (en) 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5576298A (en) 1992-11-30 1996-11-19 Research And Development Institute, Inc. At Montana State University Peptides from pseudomonas syringae possessing broad-spectrum antibiotic activity
SE9300012D0 (sv) 1993-01-05 1993-01-05 Astra Ab New peptides
US5750648A (en) 1993-08-20 1998-05-12 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
CA2173990A1 (en) * 1993-10-12 1995-04-20 Narasinga Rao A library of glyco-peptides useful for identification of cell adhesion inhibitors
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
US5780589A (en) 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
FR2729668A1 (fr) 1995-01-23 1996-07-26 Adir Nouveaux derives de mercaptoalcanoyldipeptides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5677286A (en) * 1995-04-27 1997-10-14 The University Of Michigan Glycosylated analogs of camptothecin
US6143931A (en) 1997-04-16 2000-11-07 Arqule, Inc. Synthesis and use of α-ketoamide derivatives and arrays

Also Published As

Publication number Publication date
DK0819135T3 (da) 2000-05-08
RU2170234C2 (ru) 2001-07-10
DE59603678D1 (de) 1999-12-23
UA61054C2 (en) 2003-11-17
SK281785B6 (sk) 2001-07-10
DE19512484A1 (de) 1996-10-17
IS1822B (is) 2002-10-01
PL322681A1 (en) 1998-02-16
CZ291098B6 (cs) 2002-12-11
BG63048B1 (bg) 2001-02-28
US6271342B1 (en) 2001-08-07
CA2217164A1 (en) 1996-10-10
MX9707613A (es) 1997-12-31
NZ305855A (en) 1999-11-29
WO1996031532A1 (de) 1996-10-10
IS4562A (is) 1997-09-18
NO974564D0 (no) 1997-10-02
BG101892A (en) 1998-05-29
AU5397696A (en) 1996-10-23
AU713466B2 (en) 1999-12-02
SK134597A3 (en) 1998-05-06
HUP9800513A3 (en) 1998-09-28
EE9700258A (et) 1998-04-15
HUP9800513A2 (hu) 1998-06-29
TW384290B (en) 2000-03-11
EE03619B1 (et) 2002-02-15
GR3032605T3 (en) 2000-05-31
EP0819135A1 (de) 1998-01-21
NO974564L (no) 1997-11-25
JPH11502860A (ja) 1999-03-09
ATE186738T1 (de) 1999-12-15
CZ314397A3 (cs) 1998-01-14
CN1185786A (zh) 1998-06-24
EP0819135B1 (de) 1999-11-17
BR9604825A (pt) 1999-01-05
KR19980703591A (ko) 1998-11-05
PL183574B1 (pl) 2002-06-28

Similar Documents

Publication Publication Date Title
ES2140078T3 (es) Citostaticos modificados con hidratos de carbono.
NL980031I2 (nl) Fenylcarbamaten.
HN1997000099A (es) Inhibidores de metaloproteasas matriciales basados en
ES2117009T3 (es) Un ligando bifuncional de tipo dtpa.
HN1997000126A (es) Derivados de indazol
ES265371Y (es) Un instrumento para aplicar grapas de union.
BR8600703A (pt) Aparelho para limitar correntes de sobretensao em lampada incandescente iluminada por c/c.
ES8205209A1 (es) Un procedimiento para la preparacion de un derivado de ben- zamida
NO855246L (no) Forbedrede vinyldispersjonsharpikser.
IT8025515A0 (it) Procedimento per ottimizzare il consumo di carburante.
BG100248A (bg) Инхибитори на скваленсинтетаза
EA200000069A1 (ru) Способ получения 4-замещенных-1h-индол-3-глиоксамидов
SV1994000064A (es) Derivados de acidos 1-(2-fluorciclopropil)-quinolon-naftiridon carboxilicos, ref.le a 29 869-sv.
ES2158441T3 (es) Arilheterociclos con actividad herbicida.
DE3581399D1 (de) Fet-stromquelle.
IT8125750A0 (it) Odorizzante per la odorizzazione di combustibili gassosi inodori.
FI865152A7 (fi) Palavia prikettejä.
YU48719B (sh) Lizin so 6-hloro-5-fluoro-3-(2-tenoil)-2-oksindol-1-karboksamida
MX9204919A (es) Procedimiento para producir refrigeracion.
AR003807A1 (es) Citostaticos modificados con hidratos de carbono.
SU1066281A1 (ru) Двигатель
JPS52142880A (en) Fluorescent lamp
ES2052657T3 (es) Estabilizacion de clorofluoroalcanos.
IT7830753V0 (it) Lampada particolarmente per illuminazione diretta e diffusa.
IT8559818V0 (it) Schiaccia vapori.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 819135

Country of ref document: ES